For the Inventor, By the Inventor

Enter assignee name

Bridgewater, NJ, United States of America

Aventis Pharmaceuticals Inc.

Calculating rank

USPTO Granted Patents = 207

% Expired Patents = 38.2

CIPO Patents = 69

EPO Patents = 25

Trademarks = 7

Forward Citations = 1,949

Loading Chart...

Loading Chart...

430 inventors (with patents filed for the assignee):

Yulin Chiang (16 out of 98 patents)

Kenneth J Bordeau (13 out of 54 patents)

Joseph T Strupczewski (11 out of 83 patents)

4. Michael R Myers (11 out of 37 patents)

5. Alfred P Spada (11 out of 52 patents)

6. John G Jurcak (11 out of 33 patents)

7. Martin P Maguire (9 out of 24 patents)

8. David M Fink (9 out of 28 patents)

9. Edward J Glamkowski (8 out of 116 patents)

10. Norton P Peet (8 out of 87 patents)

11. Raymond W Kosley, Jr (8 out of 66 patents)

12. Yong Mi Choi-Sledeski (7 out of 16 patents)

13. Gregory Bernard Poli (7 out of 13 patents)

14. Timothy A Gillespy (7 out of 8 patents)

15. Sukanthini Thurairatnam (7 out of 13 patents)

Core Competencies:

Cardiovascular Treatments

PARP Inhibitors

Diabetes Management

Pharmaceutical Composition

Nuclear Factor Kappa B

Dopamine Agonists

Prostaglandin Receptor

Kinase Inhibitors

Heterocyclic Compounds

Antibodies

Retroviral Vectors

Amino Acid Derivatives

207 patents: Sort by Forward Citations

1. 8828974 - Substituted propane phosphinic acid derivatives (2014-09-09),

2. 8809270 - Method for reducing cardiovascular morbidity and mortality in prediaetic patients and patients with type 2 diabetes (2014-08-19),

3. 8642739 - Nuclear factor κB inducing factor (2014-02-04),

4. 8623831 - Nuclear factor κB inducing factor (2014-01-07),

5. 8343494 - Antibodies against LLG polypeptides of the triacylglycerol lipase family (2013-01-01),

6. 8288425 - Benzimidazoles (2012-10-16),

7. 8202863 - Pyrimidine amide compounds as PGDS inhibitors (2012-06-19),

8. 8193183 - 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists (2012-06-05),

9. 8183231 - Substituted propane phosphinic acid derivatives (2012-05-22),

10. 8173682 - Substituted pyridones as inhibitors of poly(ADP-ribose) polymerase (PARP) (2012-05-08),

11. 8053458 - Dipyrazole compounds and their use as central nervous system agents (2011-11-08),

12. 8008491 - Substituted AZA-indoles as inhibitors of poly(ADP-ribose) polymerase (PARP) (2011-08-30),

13. 8008340 - 3-arylthioindole-2-carboxamide derivatives and analogs thereof as inhibitors of casein kinase I (2011-08-30),

14. 7989584 - AKT nucleic acids, polypeptides, and uses thereof (2011-08-02),

15. 7977310 - Method for reducing cardiovascular morbidity and mortality in prediabetic patients and patients with type 2 diabetes (2011-07-12),

Company Overview

Aventis Pharmaceuticals Inc., headquartered in Bridgewater, NJ, specializes in the development and manufacturing of innovative pharmaceutical compounds. The company focuses on critical areas such as cardiovascular treatments, diabetes management, and advanced therapies involving PARP inhibitors and kinase inhibitors. With a commitment to addressing complex health challenges, Aventis also explores mechanisms involving nuclear factor kappa B and dopamine agonists, aiming to enhance patient outcomes through targeted pharmaceutical compositions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

207 Patents

#2 in Bridgewater, NJ

#93 in New Jersey

#2,005 in US

#4,114 in the World

Bridgewater, NJ, United States of America

Aventis Pharmaceuticals Inc.

Forward Citations = 1,949

430 inventors:

Yulin Chiang (16 out of 98 patents)

Kenneth J Bordeau (13 out of 54 patents)

Joseph T Strupczewski (11 out of 83 patents)

4. Michael R Myers (11 out of 37 patents)

5. Alfred P Spada (11 out of 52 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Aventis Pharmaceuticals Inc.. Retrieved from https://idiyas.com/company/aventis-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…